Forecasting cholera conjugate vaccine adoption across 39 countries
Scenario-based modeling points to a staggered rollout for cholera conjugate vaccine adoption in 39 low- and middle-income countries, with country readiness shaped by prior vaccine experience, eligibility for Gavi support, and local cholera burden. The analysis used oral cholera vaccine introduction as a proxy for how quickly a conjugate platform might move from prequalification to country use, then standardized those estimates against observed timelines for similar post-prequalification vaccine transitions. In practical terms, the work tries to answer a procurement question as much as a clinical one: where will demand emerge first, and how quickly can health systems absorb a new vaccine formulation?
The median projected time to CCV introduction was 6.9 years after WHO prequalification. Twelve countries were projected to introduce within five years. Those estimates do not describe guaranteed uptake; they describe a plausible adoption window built from historical behavior and current country characteristics. The forecasting framework identified earlier introduction in countries with Gavi eligibility, more prior oral cholera vaccine experience, and higher cholera intensity. Each of those factors fits a familiar programmatic pattern: financing support lowers procurement friction, prior campaign experience shortens administrative lead time, and heavier disease pressure increases political urgency.
A vaccine can only move as fast as the system around it.
How the projection model translated past vaccine behavior into future timelines
Investigators fitted accelerated failure time models to estimate introduction timing, then used observed post-WHO-prequalification intervals from analogous vaccine transitions to standardize the estimates. That approach matters because raw country comparisons can be misleading. A nation with a strong immunization platform may appear “ready” on paper, yet still face shipment, financing, and scheduling delays once a new product reaches the market. Standardization against historical vaccine transitions anchors the forecast in real-world uptake patterns instead of relying on disease burden alone.
The model also extended beyond a simple yes-or-no question about adoption. For the typhoid-cholera combination, the analysis built a TCV/CCV introduction priority index based on typhoid burden and previous vaccination experience. That index helped separate countries more likely to move directly into the combined product from those likely to begin with CCV alone before considering a later transition. The result was a three-pathway framework: CCV introduction followed by transition to TCV/CCV, direct TCV/CCV introduction, and continued CCV use without TCV/CCV introduction during the study period.
Typhoid-cholera combination vaccines followed three distinct pathways
The combined vaccine forecast is the most operationally interesting part of the analysis because it reflects how immunization programs often adopt new products in stages rather than all at once. Some countries may start with CCV as the most immediately relevant option for cholera control, then shift to a combination product if typhoid burden, financing, regulatory readiness, and delivery capacity line up. Others may skip the intermediate step and move directly to a combined formulation if the program sees value in broader enteric disease protection from the outset. A third group may remain with CCV only during the analysis horizon, either because the combined product is not yet prioritized or because the surrounding infrastructure does not support another platform change.
Projected introduction timing did not consistently align with the semi-quantitative routine integration barrier scores for either vaccine. In other words, a country with relatively lower measured barriers was not necessarily projected to introduce earlier, and a country with more apparent obstacles was not automatically forecast to lag behind. That disconnect suggests that adoption timing is influenced by more than the direct integration hurdles captured in the scoring approach. Financing windows, donor alignment, outbreak history, procurement decisions, and policy sequencing likely shape the real timeline as much as the formal readiness profile.
Why these forecasts matter for supply planning and financing decisions
For manufacturers and global buyers, the median 6.9-year introduction estimate is more than an abstract number. It provides a planning horizon for antigen production, fill-finish capacity, pricing assumptions, and distribution logistics. If 12 countries may adopt within five years, demand could cluster early rather than arrive evenly across the 39-country set. That kind of uneven uptake can strain supply planning if production forecasts assume a smooth curve. It can also leave ministries waiting for product availability if manufacturing assumptions are too conservative.
For country programs, the forecast is a cue to prepare rather than a verdict on readiness. Countries projected to adopt earlier may need regulatory review, financing negotiations, immunization schedule planning, and cold-chain assessment sooner than expected. Countries projected to move later still have value in using the interval to build delivery capacity and clarify whether a cholera-only strategy or a combined typhoid-cholera approach best fits their epidemiology. The analysis does not replace product-specific country decisions; it creates a structured way to anticipate them.
The burden signal was not uniform across settings.
Recalibration will be necessary as product-specific evidence accumulates
The projections are explicitly scenario-based, which makes them useful for early planning and vulnerable to change as more direct evidence emerges. The model is grounded in analogous vaccine behavior, not in observed CCV or TCV/CCV adoption data across the full set of countries. That limitation is built into the design, and it means the output should be treated as a forward-looking map rather than a fixed schedule. As product characteristics, regulatory pathways, pricing, and country policies become clearer, the forecast will need to be recalibrated.
Even so, the study offers a concrete starting point for demand forecasting, market assessment, manufacturing strategy, and introduction preparedness. It identifies where early interest is most likely to emerge and where additional programmatic or financing support may be needed before deployment becomes feasible. In vaccine policy, especially for enteric infections that often compete with many other public health priorities, those planning signals can shape whether introduction happens smoothly or arrives after the moment of highest need has passed.